search
Back to results

A Sardine Diet Intervention Study to Assess Benefits to the Metabolic Profile in Type 2 Diabetes Mellitus Patients (PILCHARDUS)

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Sardine diet
Sponsored by
Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring Diet, Sardine, Type 2 diabetes

Eligibility Criteria

40 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age > 40 years and < 85
  • BMI ≥ 25 and < 35
  • Patients diagnosed with type 2 diabetes at onset or treated only by diet
  • HbA1c between 6.0 and 8.0% (based on the last measured and documented laboratory measurement of the previous 3 months)
  • Usual consumption ≤ 3 fish per week

Exclusion Criteria:

  • T2D treated with antidiabetic oral drugs and/or insulin
  • Current or previous (within 3 months) intake of omega 3 suplements
  • Known allergy or intolerance to fish or fish protein
  • Diagnosis of active neoplasic disease
  • Suffering from an acute illness which requires a recovery period higher than one week
  • Currently chronic treatment with oral steroids or nonesteroidal anti-inflammatory for more than 5 days, at least 1 month before randomization
  • Pregnant or breast-feeding patients
  • Serious acute vascular events (cardiac or cerebral) diagnosed previous 2 months before the randomization
  • Current or previous (within 6 months) participation in another study
  • Chronic renal insufficiency (creatinine >1,5 mg/dl)
  • Any conditions that the investigator considers may render the patient unable to complete the study

During the interventional study, based on current standards of T2D care, doctors will introduce anti-diabetic oral drugs or insulin into the patient's treatment, where they consider it to be necessary.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    Sardine diet

    Control diet

    Arm Description

    Subjects follow general dietary recommendations for diabetes including a fixed amount of sardine in daily meals (100g per day, 5 days a week) as part of their usual diet.

    Subjects only follow general dietary recommendations for diabetes.

    Outcomes

    Primary Outcome Measures

    Change from baseline in glycated hemoglobin (HbA1c) at 6 months
    Change from baseline in fasting glucose at 6 months
    Change from baseline in fasting insulin at 6 months

    Secondary Outcome Measures

    Change from baseline in adiponectin at 6 months
    Change from baseline in leptin at 6 months
    Change from baseline in ultra sensitive C-reactive protein (us-CRP) at 6 months
    Change from baseline in interleukin-6 (IL-6) at 6 months
    Change from baseline in interleukin-8 (IL-8) at 6 months
    Change from baseline in interleukin-10 (IL-10) at 6 months
    Change from baseline in tumor necrosis factor alpha (TNFα) at 6 months
    Change from baseline in erytrocite membrane fatty acid composition (EMFA) at 6 months
    Change from baseline in specific bacterial groups of gut microbiota at 6 months
    Change from baseline in total cholesterol at 6 months
    Change from baseline in LDL cholesterol at 6 months
    Change from baseline in HDL cholesterol at 6 months
    Change from baseline in triglycerides at 6 months
    Change from baseline in blood pressure at 6 months

    Full Information

    First Posted
    October 31, 2014
    Last Updated
    January 28, 2015
    Sponsor
    Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02294526
    Brief Title
    A Sardine Diet Intervention Study to Assess Benefits to the Metabolic Profile in Type 2 Diabetes Mellitus Patients
    Acronym
    PILCHARDUS
    Official Title
    PILCHARDUS STUDY: A Sardine Diet Intervention Study to Assess Benefits to the Metabolic Profile in Type 2 Diabetes Mellitus Patients
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    November 2012 (undefined)
    Primary Completion Date
    November 2013 (Actual)
    Study Completion Date
    November 2013 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Work hypothesis A diet rich in sardine will improve the metabolic control in type 2 diabetes patients.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 2 Diabetes
    Keywords
    Diet, Sardine, Type 2 diabetes

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    35 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Sardine diet
    Arm Type
    Experimental
    Arm Description
    Subjects follow general dietary recommendations for diabetes including a fixed amount of sardine in daily meals (100g per day, 5 days a week) as part of their usual diet.
    Arm Title
    Control diet
    Arm Type
    No Intervention
    Arm Description
    Subjects only follow general dietary recommendations for diabetes.
    Intervention Type
    Other
    Intervention Name(s)
    Sardine diet
    Intervention Description
    Diet rich in sardine: 100g/day of sardine 5 times a week
    Primary Outcome Measure Information:
    Title
    Change from baseline in glycated hemoglobin (HbA1c) at 6 months
    Time Frame
    Baseline and 6 months
    Title
    Change from baseline in fasting glucose at 6 months
    Time Frame
    Baseline and 6 months
    Title
    Change from baseline in fasting insulin at 6 months
    Time Frame
    Baseline and 6 months
    Secondary Outcome Measure Information:
    Title
    Change from baseline in adiponectin at 6 months
    Time Frame
    Baseline and 6 months
    Title
    Change from baseline in leptin at 6 months
    Time Frame
    Baseline and 6 months
    Title
    Change from baseline in ultra sensitive C-reactive protein (us-CRP) at 6 months
    Time Frame
    Baseline and 6 months
    Title
    Change from baseline in interleukin-6 (IL-6) at 6 months
    Time Frame
    Baseline and 6 months
    Title
    Change from baseline in interleukin-8 (IL-8) at 6 months
    Time Frame
    Baseline and 6 months
    Title
    Change from baseline in interleukin-10 (IL-10) at 6 months
    Time Frame
    Baseline and 6 months
    Title
    Change from baseline in tumor necrosis factor alpha (TNFα) at 6 months
    Time Frame
    Baseline and 6 months
    Title
    Change from baseline in erytrocite membrane fatty acid composition (EMFA) at 6 months
    Time Frame
    Baseline and 6 months
    Title
    Change from baseline in specific bacterial groups of gut microbiota at 6 months
    Time Frame
    Baseline and 6 months
    Title
    Change from baseline in total cholesterol at 6 months
    Time Frame
    Baseline and 6 months
    Title
    Change from baseline in LDL cholesterol at 6 months
    Time Frame
    Baseline and 6 months
    Title
    Change from baseline in HDL cholesterol at 6 months
    Time Frame
    Baseline and 6 months
    Title
    Change from baseline in triglycerides at 6 months
    Time Frame
    Baseline and 6 months
    Title
    Change from baseline in blood pressure at 6 months
    Time Frame
    Baseline and 6 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    40 Years
    Maximum Age & Unit of Time
    85 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age > 40 years and < 85 BMI ≥ 25 and < 35 Patients diagnosed with type 2 diabetes at onset or treated only by diet HbA1c between 6.0 and 8.0% (based on the last measured and documented laboratory measurement of the previous 3 months) Usual consumption ≤ 3 fish per week Exclusion Criteria: T2D treated with antidiabetic oral drugs and/or insulin Current or previous (within 3 months) intake of omega 3 suplements Known allergy or intolerance to fish or fish protein Diagnosis of active neoplasic disease Suffering from an acute illness which requires a recovery period higher than one week Currently chronic treatment with oral steroids or nonesteroidal anti-inflammatory for more than 5 days, at least 1 month before randomization Pregnant or breast-feeding patients Serious acute vascular events (cardiac or cerebral) diagnosed previous 2 months before the randomization Current or previous (within 6 months) participation in another study Chronic renal insufficiency (creatinine >1,5 mg/dl) Any conditions that the investigator considers may render the patient unable to complete the study During the interventional study, based on current standards of T2D care, doctors will introduce anti-diabetic oral drugs or insulin into the patient's treatment, where they consider it to be necessary.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Ramon Gomis, Professor
    Organizational Affiliation
    CIBERDEM - IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer) - Hospital Clínic of Barcelona
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    27090218
    Citation
    Balfego M, Canivell S, Hanzu FA, Sala-Vila A, Martinez-Medina M, Murillo S, Mur T, Ruano EG, Linares F, Porras N, Valladares S, Fontalba M, Roura E, Novials A, Hernandez C, Aranda G, Siso-Almirall A, Rojo-Martinez G, Simo R, Gomis R. Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naive patients with type 2 diabetes: a pilot randomized trial. Lipids Health Dis. 2016 Apr 18;15:78. doi: 10.1186/s12944-016-0245-0.
    Results Reference
    derived

    Learn more about this trial

    A Sardine Diet Intervention Study to Assess Benefits to the Metabolic Profile in Type 2 Diabetes Mellitus Patients

    We'll reach out to this number within 24 hrs